FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京同仁堂科技發展股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 652,080,000 RMB | | | 1 RMB | | 652,080,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 652,080,000 RMB | | | 1 RMB | | 652,080,000 | | 2. 股份分類 ...

Core Insights - Tongrentang Technology has made significant progress in the capacity layout of liquid preparations, with the new oral liquid production line expected to submit GMP compliance inspection application by the end of the year [2][6] - The market for traditional Chinese medicine liquid preparations, including oral liquids, has seen continuous growth, with sales exceeding 20 billion yuan in 2023 and expected to maintain stable growth in 2024 [4] - The company has established a closed-loop production system suitable for continuous production of traditional Chinese medicine, enhancing production efficiency and flexibility [6] Company Developments - The new production line will increase the company's total liquid preparation production capacity to 240 million bottles annually, with a maximum daily capacity of 800,000 bottles [2] - Key equipment upgrades include a new water bath sterilizer with a 42.8% increase in capacity and an AI-driven automatic light inspection machine for optimized detection parameters [6] - The company is advancing its "smart production line" initiative, focusing on data integration across the entire supply chain from planting to production and consumption [6] Market Trends - The main categories driving the market include medications for respiratory diseases, tonics for energy and blood, and digestive system diseases [4] - Tongrentang Technology's oral liquid products, such as Shenmai Drink and Children's Cough Syrup, are gaining traction due to their quick efficacy, precise dosing, and ease of use, aligning with modern consumer demands [4]

Core Insights - Tongrentang Technology has successfully completed the trial operation of its export product workshop, marking a significant step towards the official production of its "export product production and R&D base" [1][3] Group 1: Production Capabilities - The company produces nearly 200 varieties of traditional Chinese medicine, covering over 20 dosage forms, which supports its overseas business growth [3] - The newly established export product production and R&D base has a construction area of over 1,400 square meters and is equipped with advanced pharmaceutical equipment and testing instruments [3][6] - The base is designed to meet the production and testing needs of 66 product specifications, including water honey pills, granules, and tablets, ensuring a robust supply for overseas markets [3][6] Group 2: Market Adaptation - The establishment of the export base allows for production tailored to the regulatory requirements of target markets, creating a more specialized supply system [3] - The base focuses on producing dosage forms that are more acceptable to overseas consumers, addressing cultural differences in consumption habits [3] Group 3: Quality Assurance - The trial operation tested the stability, production efficiency, and product quality, with results showing uniform granule size and excellent tablet formation [5][6] - The successful trial operation validates the "practical capabilities" of the export product workshop, enhancing the confidence in Tongrentang's international expansion [6] Group 4: Strategic Vision - The establishment of a dedicated export base enables the company to quickly respond to international market changes and systematically address the barriers faced by traditional Chinese medicine in global markets [6] - The company aims to transition from "able to export" to "good export" and ultimately to "brand export," fostering long-term trust and brand premium in international markets [6] - Future plans include optimizing production processes and advancing supporting work to achieve full production at the base, enhancing the international competitiveness of traditional Chinese medicine [6]

Core Insights - Tongrentang Technology has made significant progress in the capacity layout of liquid preparations, with the new oral liquid production line expected to submit GMP compliance inspection application by the end of the year [1] - The market for traditional Chinese medicine liquid preparations, including oral liquids, has seen continuous growth, with sales exceeding 20 billion yuan in 2023 and expected to maintain stable growth in 2024 [3] - The company has established a closed-loop production system suitable for continuous production of traditional Chinese medicine, enhancing production efficiency and flexibility in response to market demands [6] Group 1 - The new production line will increase the company's total capacity to four liquid preparation lines, with a maximum daily output of 800,000 bottles and an annual designed capacity exceeding 240 million bottles [1] - Key product categories driving market growth include medications for respiratory diseases, tonics, and digestive system diseases, with Tongrentang's oral liquid products benefiting from their quick efficacy and ease of use [3] - The introduction of advanced equipment, such as a new water bath sterilizer with a 42.8% increase in capacity and AI-enhanced automatic inspection machines, will further optimize production processes [6] Group 2 - The company is advancing its "smart production line" initiative, integrating data across the entire supply chain from cultivation to production, distribution, and consumption [6] - The deployment of a visual "cockpit" system in the workshop allows for real-time monitoring of production progress and key milestones, supporting resource utilization and cost control [6] - By embedding technological innovation into its operations, Tongrentang Technology aims to strengthen its competitive advantage in the modern traditional Chinese medicine sector, enhancing product innovation and operational efficiency [6]

Core Insights - The company is focusing on strategic transformation of its marketing system since 2025, combining product focus and channel optimization to enhance brand value and market competitiveness [1][5] - The company has established a multi-layered product matrix around key products, which includes nearly 300 varieties, laying a foundation for brand value release [1] - The optimization of channels is a key aspect of the marketing reform, with measures implemented to control channels and terminals, resulting in a more efficient sales network [1][5] Product Development - The company is concentrating on core products such as An Gong Niu Huang Wan, Xi Huang Wan, Liu Wei Di Huang Wan, and Jing Zhi Niu Huang Jie Du Wan, among others [1] - A systematic review of nearly 300 product varieties has been conducted to enhance product competitiveness [1] Channel Optimization - In 2025, the company implemented six targeted measures centered on "controlling channels and terminals," which include strengthening distributor admission and dynamic management [1] - The optimization of first and second-level distributors has achieved preliminary results, creating a "flat, efficient, and scientifically controllable" sales network [1] Terminal Network Development - The company has conducted 1,759 market activities, including 177 in prefecture-level cities, 100 in county areas, and 1,482 in communities, successfully developing 22 blank markets in counties [2][3] - Sales in grassroots markets have significantly increased year-on-year, with a notable rise in the proportion of terminal customers, particularly from third and fourth-tier cities and rural areas [2] "Double Thousand Project" - The company has established a terminal network covering 31 provinces and 273 prefecture-level cities, reaching over 230,000 chain and terminal stores [4] - The "Double Thousand Project" focuses on empowering 1,000 pharmacies and 1,000 medical clinics, enhancing product management, professional services, and brand marketing [4][5] - The project aims to improve product coverage and market responsiveness through resource packages that include priority supply guarantees and health culture lectures [4]

Group 1 - The core viewpoint of the news is that Tongrentang Technology (01666.HK) reported its unaudited financial results for the nine months ending September 30, 2025, showing significant revenue and profit figures [1] - The unaudited operating revenue for the group was approximately RMB 4.98 billion, with an operating cost of about RMB 2.991 billion, resulting in a net profit attributable to the parent company of approximately RMB 416 million [1] - As of September 30, 2025, the total unaudited assets of the group were approximately RMB 14.596 billion [1] Group 2 - As of October 28, 2025, Tongrentang Technology's stock closed at HKD 4.63, down 0.64%, with a trading volume of 1.5952 million shares and a trading value of HKD 7.3941 million [1] - Investment banks primarily rate the stock as outperforming the industry, with one bank giving an outperform rating in the last 90 days and a target average price of HKD 6.3 [1] - CITIC Securities recently issued a buy rating for Tongrentang Technology [1] Group 3 - The market capitalization of Tongrentang Technology is HKD 2.93 billion, ranking 6th in the Chinese medicine II industry [2] - Key performance indicators show that the company's ROE is 5.92%, which is higher than the industry average of 5.51% [2] - The company's net profit margin is 12.95%, slightly below the industry average of 13.75%, and its gross profit margin is 38.16%, significantly lower than the industry average of 51.2% [2]

Core Viewpoint - Tong Ren Tang Technologies (600085) reported its financial results for the nine months ending September 30, 2025, indicating a strong revenue performance and profitability [1] Financial Performance - The group's unaudited revenue for the nine months was approximately RMB 4.98 billion [1] - The unaudited cost of goods sold was approximately RMB 2.991 billion [1] - The unaudited net profit attributable to the owners of the parent company was approximately RMB 416 million [1] - As of September 30, 2025, the group's unaudited total assets were approximately RMB 14.596 billion [1]

Core Viewpoint - Tongrentang Technology (01666) reported its financial results for the nine months ending September 30, 2025, showing significant revenue and profit figures [1] Financial Performance - The company's unaudited operating revenue reached approximately RMB 4.98 billion for the nine months ending September 30, 2025 [1] - The unaudited operating costs for the same period were approximately RMB 2.991 billion [1] - The unaudited net profit attributable to the parent company was approximately RMB 416 million [1] - As of September 30, 2025, the company's unaudited total assets amounted to approximately RMB 14.596 billion [1]

Core Viewpoint - Tongrentang Technology (01666.HK) reported its financial results for the nine months ending September 30, 2025, showing significant revenue and profit figures [1] Financial Performance - The company recorded an unaudited revenue of approximately RMB 497,964 million for the nine months ending September 30, 2025 [1] - The unaudited cost of goods sold was approximately RMB 299,069 million during the same period [1] - The unaudited net profit attributable to the owners of the parent company was approximately RMB 41,626 million [1] - As of September 30, 2025, the company's unaudited total assets amounted to approximately RMB 1,459,589 million [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部 或任何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 有關二零二五年三季度財務信息之公告 北京同仁堂科技發展股份有限公司（「本公司」）根據《證券及期貨條例》（香 港法例第571章）第XIVA部及香港聯合交易所有限公司證券上市規則第13.09條 作出本公告。 張毅 董事長 （股份代號：1666） 本公司控股股東北京同仁堂股份有限公司將於二零二五年十月三十一日在上海 證券交易所公佈其截至二零二五年九月三十日止九個月未經審計之三季度業 績，該業績包含本公司及其附屬公司（「本集團」）截至二零二五年九月三十日 止九個月未經審計的財務信息。為保證本公司全體股東公平、及時地知曉本公司 信息，本公司特此公佈以下財務信息：根據中華人民共和國財政部頒佈的《中華 人民共和國企業會計準則》，截至二零二五年九月三十日止九個月，本集團未經 審計營業收入約人民幣497,964萬元，未經審計營業成本約人民幣299,069萬元， 及未經審計歸屬於母公司所有者的淨利潤約人民幣41,626萬元 ...